GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
35.27
-0.09 (-0.25%)
Jan 31, 2025, 4:00 PM EST - Market closed
GSK Employees
GSK plc had 70,212 employees as of December 31, 2023. The number of employees increased by 812 or 1.17% compared to the previous year.
Employees
70,212
Change (1Y)
812
Growth (1Y)
1.17%
Revenue / Employee
$597,707
Profits / Employee
$47,933
Market Cap
71.26B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 70,212 | 812 | 1.17% |
Dec 31, 2022 | 69,400 | -20,696 | -22.97% |
Dec 31, 2021 | 90,096 | -3,970 | -4.22% |
Dec 31, 2020 | 94,066 | -5,371 | -5.40% |
Dec 31, 2019 | 99,437 | 3,947 | 4.13% |
Dec 31, 2018 | 95,490 | -2,972 | -3.02% |
Dec 31, 2017 | 98,462 | -838 | -0.84% |
Dec 31, 2016 | 99,300 | -1,955 | -1.93% |
Dec 31, 2015 | 101,255 | 3,334 | 3.40% |
Dec 31, 2014 | 97,921 | -1,530 | -1.54% |
Dec 31, 2013 | 99,451 | -37 | -0.04% |
Dec 31, 2012 | 99,488 | 2,099 | 2.16% |
Dec 31, 2011 | 97,389 | 928 | 0.96% |
Dec 31, 2010 | 96,461 | -3,452 | -3.46% |
Dec 31, 2009 | 99,913 | 910 | 0.92% |
Dec 31, 2008 | 99,003 | -4,480 | -4.33% |
Dec 31, 2007 | 103,483 | 788 | 0.77% |
Dec 31, 2006 | 102,695 | 1,967 | 1.95% |
Dec 31, 2005 | 100,728 | 709 | 0.71% |
Dec 31, 2004 | 100,019 | -900 | -0.89% |
Dec 31, 2003 | 100,919 | -3,580 | -3.43% |
Dec 31, 2002 | 104,499 | -2,971 | -2.76% |
Dec 31, 2001 | 107,470 | -47 | -0.04% |
Dec 31, 2000 | 107,517 | -1,524 | -1.40% |
Dec 31, 1999 | 109,041 | -7,780 | -6.66% |
Dec 31, 1998 | 116,821 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
GSK News
- 5 days ago - Influenza Vaccines Market Analysis 2025-2032: GlaxoSmithKline's Influenza Vaccines Sales Declined in 2024, Driven by Competitive Pressure and Volume Phasing in the US and Lower Demand - GlobeNewsWire
- 11 days ago - Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last? - CNBC
- 18 days ago - Hallucinations in AI: How GSK is addressing a critical problem in drug development - VentureBeat
- 18 days ago - Healthy Returns: From Eli Lilly to Amazon, here are the latest health-care deals - CNBC
- 18 days ago - GSK plc (GSK) 43rd Annual J.P. Morgan Healthcare Conference (Transcript) - Seeking Alpha
- 19 days ago - Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 - Seeking Alpha
- 19 days ago - Drugmakers rush to sign deals on first day of industry conference - Reuters
- 19 days ago - GSK to buy US biotech firm IDRx for up to $1.15 billion - Reuters